Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BGBIO.OL
- Price
- 1.64
- Stock movement up
- +0.03 (1.61%)
- Company name
- Bergenbio ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 64.26M
- Ent værdi
- -92.65M
- Pris/omsætning
- 123.34
- Pris/bog
- 0.37
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -29.48%
- 1 års afkast
- -90.25%
- 3 års afkast
- -80.94%
- 5 års afkast
- -60.96%
- 10 års afkast
- -
Senest opdateret: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
BGBIO.OL betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 123.34 |
| Pris til egenkapital | 0.37 |
| EV i forhold til salg | -177.84 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 39.09M |
| EPS (TTM) | -3.98 |
| FCF pr. aktie (TTM) | -4.27 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 521.00K |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -162.16M |
| Nettoindkomst (TTM) | -155.41M |
| EPS (TTM) | -3.98 |
| EPS (1 år frem) | -5.02 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | -31124.18% |
| Fortjenstmargin (TTM) | -29828.22% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 200.12M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 218.25M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 218.47M |
| Kreditor | 8.62M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 43.21M |
| Sum gæld | 43.21M |
| Aktionærernes egenkapital | 175.26M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -166.76M |
| Investeringsudgifter (TTM) | 0.00 |
| Fri pengestrøm (TTM) | -166.76M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -88.67% |
| Afkast af aktiver | -71.13% |
| Afkast af investeret kapital | -88.67% |
| Kontant afkast af investeret kapital | -95.15% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 1.60 |
| Daglig høj | 1.65 |
| Daglig lav | 1.55 |
| Daglig volumen | 179K |
| Højeste gennem alle tider | 586.68 |
| 1 års analytiker estimat | 20.00 |
| Beta | 1.64 |
| EPS (TTM) | -3.98 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 21 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BGBIO.OL | S&P500 | |
| Nuværende prisfald fra top notering | -99.72% | -10.49% |
| Højeste prisfald | -99.75% | -56.47% |
| Højeste efterår dato | 11 Mar 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -60.47% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 118 days | 12 days |
| Maks. tid til nyt højdepunkt | 1725 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
64.26M
Markedsværdi kategori
Small-cap
Beskrivelse
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
Personale
15
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been ...
7. januar 2025
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø...
20. november 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quar...
13. november 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from th...
7. oktober 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quart...
21. august 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a ...
20. august 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and S...
29. juli 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quar...
29. maj 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clin...
28. maj 2024